Emu Oil Improves Clinical Indicators of Disease in a Mouse Model of Colitis-Associated Colorectal Cancer.

Emu Oil Improves Clinical Indicators of Disease in a Mouse Model of Colitis-Associated Colorectal Cancer. Dig Dis Sci. 2017 Dec 06;: Authors: Chartier LC, Howarth GS, Lawrance IC, Trinder D, Barker SJ, Mashtoub S Abstract BACKGROUND/AIMS: Ulcerative colitis is a remitting and relapsing inflammatory bowel disorder. Current treatments are limited, and if poorly controlled, colitis may progress to colorectal cancer. Previously, Emu Oil protected the intestine in experimental models of gut damage. We aimed to determine whether Emu Oil could reduce the severity of chronic colitis and prevent the onset…

Read More

Fourteen-Year Anti-TNF Therapy in Crohn’s Disease Patients: Clinical Characteristics and Predictive Factors.

Related Articles Fourteen-Year Anti-TNF Therapy in Crohn’s Disease Patients: Clinical Characteristics and Predictive Factors. Dig Dis Sci. 2017 Dec 05;: Authors: Osamura A, Suzuki Y Abstract BACKGROUND: Crohn’s disease (CD) is an intractable disease that requires long-term treatment. Tumor necrosis factor (TNF) inhibitors have strong efficacy and are widely used for CD treatment. However, a loss of response is one of the issues in long-term TNF therapy. To identify the factors affecting the efficacy of long-term CD treatment with TNF inhibitors, we conducted a retrospective study of treatment outcomes and…

Read More

Association Between Adipokines Levels with Inflammatory Bowel Disease (IBD): Systematic Reviews.

Association Between Adipokines Levels with Inflammatory Bowel Disease (IBD): Systematic Reviews. Dig Dis Sci. 2017 Oct 30;: Authors: Morshedzadeh N, Rahimlou M, Asadzadeh Aghdaei H, Shahrokh S, Reza Zali M, Mirmiran P Abstract BACKGROUND: A combination of genetic and environmental factors is involved in the etiology of inflammatory bowel disease (IBD). Recent studies have shown that adipocytes play a crucial role, by actively participating in systemic immune responses in IBD patients. But findings remain controversial. To the best of our knowledge, no systematic review has evaluated the roles of adipokines…

Read More

Isolated Acute Terminal Ileitis Without Preexisting Inflammatory Bowel Disease Rarely Progresses to Crohn’s Disease.

Isolated Acute Terminal Ileitis Without Preexisting Inflammatory Bowel Disease Rarely Progresses to Crohn’s Disease. Dig Dis Sci. 2017 Oct 24;: Authors: Tse CS, Deepak P, Smyrk TC, Raffals LE Abstract BACKGROUND: Isolated acute terminal ileitis without chronic features of inflammation poses a diagnostic challenge. Few studies have investigated the clinical significance of this entity in patients without history of inflammatory bowel disease. AIMS: We sought to elucidate the long-term prognosis of patients with isolated acute terminal ileitis, its rate of progression to Crohn’s disease, and the factors associated with terminal…

Read More

Ocular, Auricular, and Oral Manifestations of Inflammatory Bowel Disease.

Ocular, Auricular, and Oral Manifestations of Inflammatory Bowel Disease. Dig Dis Sci. 2017 Oct 24;: Authors: Fine S, Nee J, Thakuria P, Duff B, Farraye FA, Shah SA Abstract Inflammatory bowel disease (IBD) is primarily a disease of the gastrointestinal tract, though it can often affect other organ systems. These extraintestinal manifestations occur in a quarter to one-third of patients with Crohn’s disease and ulcerative colitis. While musculoskeletal and dermatologic manifestations are the most common, it is also important to be cognizant of head, eye, ear, nose, and throat (HEENT)…

Read More

Out-of-Pocket Cost Is a Barrier to Therapeutic Drug Monitoring in Inflammatory Bowel Disease.

Out-of-Pocket Cost Is a Barrier to Therapeutic Drug Monitoring in Inflammatory Bowel Disease. Dig Dis Sci. 2017 Oct 20;: Authors: Campbell JP, Burton E, Wymer S, Shaw M, Vaughn BP Abstract BACKGROUND: Therapeutic drug monitoring (TDM) is increasingly performed to optimize biologic therapy in inflammatory bowel disease (IBD). However, patients and physicians may be reluctant to perform TDM due to concerns related to potential out-of-pocket costs. AIMS: The aim of this study was to evaluate patient understanding and attitudes toward TDM in different clinical scenarios with and without potential out-of-pocket…

Read More

Depressive Symptoms Predict Anti-tumor Necrosis Factor Therapy Noncompliance in Patients with Inflammatory Bowel Disease.

Depressive Symptoms Predict Anti-tumor Necrosis Factor Therapy Noncompliance in Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2017 Oct 20;: Authors: Calloway A, Dalal R, Beaulieu DB, Duley C, Annis K, Gaines L, Slaughter C, Schwartz DA, Horst S Abstract BACKGROUND: Noncompliance in use of anti-tumor necrosis factor (anti-TNF) therapy in patients with moderate-to-severe inflammatory bowel disease (IBD) can be a factor in medication failure. Few studies have evaluated the contribution of depressive symptoms to medication noncompliance in anti-TNF therapies. METHODS: A retrospective chart review was performed in a single-center…

Read More

Risk Factors for Rescue Therapy in Crohn’s Patients Maintained on Infliximab After Withdrawal of the Immunomodulator: A Long-Term Follow-Up.

Risk Factors for Rescue Therapy in Crohn’s Patients Maintained on Infliximab After Withdrawal of the Immunomodulator: A Long-Term Follow-Up. Dig Dis Sci. 2017 Oct 06;: Authors: Fischer M, Campbell SC, Calley CSJ, Helper DJ, Chiorean MV, Fadda HM Abstract BACKGROUND: Usefulness of thiopurine and scheduled infliximab combination therapy in non-immunomodulator (IM)-naïve Crohn’s disease (CD) patients and the optimal length of dual therapy are still debated. AIMS: To determine proportion of patients developing disease flare requiring rescue therapy and risk factors associated with disease flare after de-escalation of IM from combination therapy….

Read More
<< Go Back